| Code | CSB-RA017709MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is a research-grade biosimilar to REGN-13335, designed to specifically target platelet-derived growth factor subunit B (PDGFB). PDGFB is a potent mitogenic factor that plays critical roles in cellular proliferation, migration, and survival by binding to PDGF receptors and activating downstream signaling cascades. This growth factor is essential for normal development, particularly in blood vessel formation and pericyte recruitment, but aberrant PDGFB signaling has been implicated in various pathological conditions. Dysregulated PDGFB expression is associated with fibrotic diseases, atherosclerosis, and multiple cancer types where it contributes to tumor growth, angiogenesis, and stromal remodeling in the tumor microenvironment.
REGN-13335, the reference antibody developed by Regeneron Pharmaceuticals, was designed to neutralize PDGFB activity and has been investigated for its therapeutic potential in oncology and fibrotic disorders. This biosimilar provides researchers with a valuable tool for investigating PDGFB-mediated signaling pathways, exploring disease mechanisms, and evaluating potential therapeutic strategies targeting the PDGF axis in preclinical models.
There are currently no reviews for this product.